Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas

#602

Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.

Aim(s): To evaluate the antitumor effect of everolimus, an mTOR inhibitor, in preclinical models of PDNECs.

Materials and methods: The effect of everolimus on the activity of the mTOR pathway was assessed in two endocrine tumor cell lines: STC-1 and GluTag. Grafted to immunodeficient mice, these cells induce intrahepatic tumors representative of PDNECs by their morphological characteristics, their high proliferative activity and constitutive activation of the mTOR pathway.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F,

Keywords: everolimus, poorly differentiated neuroendocrine carcinoma, preclinical study,